Precision Medicine for Childhood Cancer: Current Limitations and Future Perspectives

JCO Precis Oncol. 2024 Jan:8:e2300117. doi: 10.1200/PO.23.00117.

Martin G McCabe¹, Birgit Geoerger², Louis Chesler^{3

4}, Darren Hargrave⁵, D Williams Parsons⁶, Cornelis M van Tilburg^{7

8

9

10

11}, Gudrun Schleiermacher¹², John A Hickman¹³, Sally L George^{3

4

14}

¹ Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
² Gustave Roussy Cancer Campus, Department of Pediatric and Adolescent Oncology, INSERM U1015, Université Paris-Saclay, Villejuif, France.
³ Paediatric Oncology Experimental Medicine Centre, The Institute of Cancer Research, London, United Kingdom.
⁴ Children and Young People's Unit, The Royal Marsden Hospital, London, United Kingdom.
⁵ University College London Great Ormond Street Institute of Child Health, London, United Kingdom.
⁶ Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, TX.
⁷ Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
⁸ Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁹ German Cancer Consortium (DKTK), Heidelberg, Germany.
¹⁰ Department of Pediatric Oncology, Hematology, Immunology & Pulmonology, Heidelberg University Hospital, Heidelberg, Germany.
¹¹ National Center for Tumor Diseases (NCT), Heidelberg, Germany.
¹² SiRIC RTOP (Recherche Translationelle en Oncologie Pédiatrique), Translational Research Department, Institut Curie Research Center, PSL Research University, Institut Curie, Parbe the only one citing a postcodeis, France.
¹³ School of Biological Sciences, University of Manchester, Manchester, United Kingdom.
¹⁴ The Francis Crick Institute, London, United Kingdom.

Abstract

Greater collaboration needed to realize potential of molecular profiling initiatives for pediatric cancers.